Divis Lab Share Price Target 2025, 2026, 2030, 2040, 2050
Divi’s Laboratories Limited, a major Indian pharmaceutical company, has drawn investor and analyst interest owing to its strong growth and market position. As the firm expands its supply of high-quality APIs and intermediates, market players focus on its share price expectations.
- 1 What Is Divi’s Laboratories Ltd NSE: DIVISLAB?
- 2 Share Price Target Tomorrow
- 3 Divis Lab Share Price Target 2025
- 4 Divis Lab Share Price Target 2026
- 5 Divis Lab Share Price Target 2027
- 6 Share Price Target 2028
- 7 Share Price Target 2029
- 8 Divis Lab Share Price Target 2030
- 9 Share Price Target 2040
- 10 Share Price Target 2050
- 11 Should I Buy Divis Lab Stock?
- 12 Divi’s Laboratories Ltd Earning Results
- 13 Expert Forecasts On The Future Of Divi’s Laboratories Ltd.
- 14 Is Divis Lab Stock Good To Buy? (Bull Case & Bear Case)
- 15 Conclusion
- 16 FAQs
Fundamental Table
| Metric | Value |
| Current Share Price (₹) | 5,910 |
| Market Capitalization (₹ Cr.) | 1,56,721 |
| P/E Ratio | 93.6 |
| P/B Ratio | 10.85 |
| Dividend Yield (%) | 0.51 |
| Return on Equity (ROE) (%) | 12.2 |
| Return on Capital Employed (ROCE) (%) | 16.5 |
| Net Profit Margin (%) | 20.39 |
| Operating Profit Margin (%) | 27.60 |
Key Metrics Table
| Key Metric | FY 2024 | FY 2023 | FY 2022 |
| Total Revenue (₹ Cr.) | 8,002 | 7,974 | 8,991 |
| Profit After Tax (PAT) (₹ Cr.) | 1,576 | 1,808 | 2,948 |
| Basic EPS (₹) | 60.27 | 68.69 | 111.52 |
| Dividend Payout Ratio (%) | 50% | 44% | 27% |
| Total Debt/Equity Ratio | 0 | 0 | 0 |
Peers and Comparison Table
| Company | Market Cap (₹ Cr.) | P/E Ratio | P/B Ratio | ROE (%) |
| Divi’s Laboratories Ltd. | 1,56,721 | 93.6 | 10.85 | 12.2 |
| Aurobindo Pharma Ltd. | 77,084 | 24.5 | 3.28 | 15.0 |
| Sun Pharmaceutical Industries | 68,455 | 30.1 | 4.50 | 14.5 |
| Cipla Ltd. | 62,482 | 25.0 | 4.00 | 16.0 |
| Dr. Reddy’s Laboratories Ltd. | 58,800 | 28.0 | 5.00 | 18.0 |
What Is Divi’s Laboratories Ltd NSE: DIVISLAB?
Divi’s Laboratories Limited is a renowned pharmaceutical firm in Hyderabad, India. Dr. Murali K. Divi founded the firm in 1990 as an API and intermediate commercialization research center. It has become a leading API maker by emphasizing quality and innovation.
Divi’s Hyderabad and Visakhapatnam factories meet international regulatory requirements. The firm sells to over 100 countries, supplying major pharmaceutical corporations and other clients. Divi’s 17,000 workers, including 400 scientists, invest in research and development to improve its products and production methods.
Generic APIs, bespoke synthesis, and nutraceutical compounds are its specialties. 2021-22, Divi reported $1.2 billion in sales, a considerable revenue and market share increase. Its trustworthy supplier status has made it a worldwide pharmaceutical powerhouse.
Company Overview
- Founded: 1990
- Headquarters: Hyderabad, India
- Market Capitalization: Approximately ₹1,56,721 Crores
- Current Share Price: ₹5,910
- Industry: Pharmaceuticals
| Price Type | Change |
| Maximum | +₹26.95 |
| Minimum | -₹33.85 |
Divi’s Laboratories Limited (NSE: DIVISLAB) is a major pharmaceutical company that makes high-quality APIs. Regulatory compliance affects product approvals and operating expenses, affecting the 2025 share price projection. Competitive pressure from multinational manufacturers may also hurt market share and profitability. Exchange rate swings jeopardize the company’s overseas revenue. In 2025, its share price target would be ₹7223, as per our analysis.
By our prediction, its share price would be between ₹4955 to ₹7223 in 2025.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2025 | 4955 | 7223 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 5351 | 6248 |
| February | 5364 | 6230 |
| March | 5360 | 5940 |
| April | 4955 | 6026 |
| May | 5267 | 6247 |
| June | 5364 | 6377 |
| July | 5634 | 6415 |
| August | 5525 | 6754 |
| September | 5766 | 6850 |
| October | 5934 | 6922 |
| November | 6334 | 7121 |
| December | 6535 | 7223 |
Divi’s Laboratories Limited (NSE: DIVISLAB) is expected to reach a share price goal of ₹7,680 by 2025. Many variables affect this aim, including supply chain management, which may affect manufacturing capacities and prices. In the pharmaceutical industry, innovation and research expenditures are essential for competitiveness; delays in product launches might hurt growth. Market demand swings due to economic circumstances or healthcare trends may influence revenue streams, investor sentiment, and stock performance. In 2026, its share price target would be ₹9165, as per our analysis.
By our prediction, its share price would be between ₹6535 to ₹9165 in 2026.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2026 | 6535 | 9165 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 6535 | 7242 |
| February | 6712 | 7420 |
| March | 6822 | 7740 |
| April | 6874 | 7984 |
| May | 6920 | 8054 |
| June | 6954 | 8181 |
| July | 7084 | 8266 |
| August | 7124 | 8430 |
| September | 7424 | 8631 |
| October | 7634 | 8797 |
| November | 7834 | 8914 |
| December | 8325 | 9165 |
Increasing production capacity may improve supply chain efficiency and fulfil global API demand, affecting this aim. Strategic alliances with other pharmaceutical businesses may boost income and market share. Research and development keep the organization competitive by creating new goods and enhancing old ones. Divi’s Laboratories’ future seems bright due to these factors. In 2027, its share price target would be ₹11270, as per our analysis.
By our prediction, its share price would be between ₹8325 to ₹11270 in 2027.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2027 | 8325 | 11270 |
In 2028, its share price target would be ₹13525, as per our analysis.
By our prediction, its share price would be between ₹11048 to ₹13525 in 2028.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2028 | 11048 | 13525 |
In 2029, its share price target would be ₹16051, as per our analysis.
By our prediction, its share price would be between ₹13376 to ₹16051 in 2029.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2029 | 13376 | 16051 |
The growing demand for active pharmaceutical ingredients (APIs) due to global healthcare requirements influences this positive outlook. Strategic research and development will help Divi create and improve its products, keeping it competitive. The company’s regulatory compliance boosts its growth. However, changing legislation and global economic swings might affect performance and investor sentiment. In 2030, its share price target would be ₹18510, as per our analysis.
By our prediction, its share price would be between ₹15829 to ₹18510 in 2030.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2030 | 15829 | 18510 |
Several reasons support this long-term view, including the rising worldwide demand for active pharmaceutical ingredients (APIs) as healthcare demands change. Technology in production may raise productivity and lower costs, increasing profitability. The company’s research and development will likely lead to novel products, keeping it competitive. However, regulatory reforms and market instability might slow its expansion. In 2040, its share price target would be ₹42608, as per our analysis.
By our prediction, its share price would be between ₹39820 to ₹42608 in 2040.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2040 | 39820 | 42608 |
Many factors contribute to this long-term forecast, including pharmaceutical technology advances that improve manufacturing efficiency and lower prices. Growing global healthcare demands will boost API demand, supporting revenue growth. The corporation leads industry innovation due to its significant commitment to research and development. However, legislative reforms and market rivalry may slow its expansion. In 2050, its share price target would be ₹67913, as per our analysis.
By our prediction, its share price would be between ₹64482 to ₹67913 in 2050.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2050 | 64482 | 67913 |
Should I Buy Divis Lab Stock?
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2025 | 4955 | 7223 |
| 2026 | 6535 | 9165 |
| 2027 | 8325 | 11270 |
| 2028 | 11048 | 13525 |
| 2029 | 13376 | 16051 |
| 2030 | 15829 | 18510 |
| 2040 | 39820 | 42608 |
| 2050 | 64482 | 67913 |
Divi’s Laboratories Limited (NSE: DIVISLAB) is investing carefully and considering numerous elements. Dedicated to API and intermediate production, the firm has grown steadily.
Divi’s Laboratories has minimal debt and a solid dividend distribution, but revenue growth over the previous five years has been 9.66%. Before investing, investors should consider the company’s growth prospects, value, and market circumstances. A prudent strategy may be to wait for a price adjustment before investing.
Divi’s Laboratories Ltd Earning Results
| Financial Year | Total Revenue (₹ Cr) | Net Profit (₹ Cr) | EPS (₹) | P/E Ratio |
| FY 2020 | 5,584.05 | 1,376.54 | 51.85 | 107.56 |
| FY 2021 | 7,031.96 | 1,984.29 | 74.75 | 78.94 |
| FY 2022 | 9,073.70 | 2,960.45 | 111.52 | 52.94 |
| FY 2023 | 8,112.00 | 1,824.00 | 68.71 | 86.02 |
| FY 2024 (Estimated) | 8,184.00 | 1,600.00 | 60.27 | 93.65 |
Expert Forecasts On The Future Of Divi’s Laboratories Ltd.
Analysts and investors have noticed Divi’s Laboratories Limited (NSE: DIVISLAB)’s excellent pharmaceutical position. The firm may capitalize on worldwide pharmaceutical demand as a significant API producer. Divi’s Laboratories’ future predictions from experts:
- Analysts predict a share price objective of ₹6,400 for 2025, representing a 15% increase from current levels.
- By 2030, GLP-1 API demand is predicted to generate $800 million in revenue for the firm.
- Research and development provide Divi’s Laboratories with a competitive advantage and enhance its API line.
- Strategic relationships with large pharmaceutical companies should boost revenue and market share.
- The company’s cost-effective production procedures boost profits.
- Currency volatility, regulatory compliance issues, and global manufacturing competition threaten export revenues.
Is Divis Lab Stock Good To Buy? (Bull Case & Bear Case)
Bull Case:
- Strong financial performance, including a 67.6% year-over-year growth in net profit for Q4 FY24, showing efficient operations.
- Analysts predict a 15% increase from present levels to a target price of ₹6,400.
- The rising GLP-1 API market, projected at $800 million by 2030, presents considerable income prospects for the organization.
- Increasing mutual fund holdings imply institutional stock optimism.
- Technical analysis indicates bullish momentum, suggesting long positions with goals around ₹5,000.
Bear Case:
- The stock’s high P/E ratio suggests overvaluation relative to historical trends.
- Sales and profits have fluctuated, with some quarters declining.
- Exiting the Nifty 50 index may damage investor sentiment and liquidity.
- Failure to grow Custom Synthesis might hurt future revenues.
- Several analysts advocate “sell” ratings, signaling market caution.
Conclusion
Due to its solid market position and development prospects, Divi’s Laboratories Limited is an attractive pharmaceutical investment. The company’s strong financial performance, strategic emphasis on high-demand APIs, and research and development commitment position it for success. High valuation metrics, changeable sales patterns, and economic variables affecting market sentiment must also be considered by investors.
